Claims

1. An antibody agent or antigen-binding fragment thereof specific to Dengue virus,

which antibody agent comprises a heavy chain variable region and a light chain variable region, each of which includes complementarity determining regions (CDRs) and framework regions (FRs), wherein

the heavy chain variable region comprises CDRs whose amino acid sequences are set forth in SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25 and FRs whose amino acid sequences are set forth in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6; and

the light chain variable region comprises CDRs whose amino acid sequences are set forth in SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28 and FRs whose amino acid sequences are set forth in SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13.

2. The antibody agent or antigen-binding fragment thereof according to claim 1, which is an IgG.

3. The antibody agent or antigen-binding fragment thereof according to claim 1, which is a monoclonal antibody.

4. The antibody agent or antigen-binding fragment thereof according to claim 1, wherein the antibody agent is selected from the group consisting of: a mouse antibody, a humanized antibody, a human antibody, a purified antibody, an isolated antibody, a chimeric antibody, a polyclonal antibody, and combinations thereof.

5. The antibody agent or antigen-binding fragment thereof according to claim 1, wherein the antibody agent or the antigen-binding fragment thereof is selected from the group consisting of: a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment, a Fd fragment, a Fd' fragment, a Fv fragment, a dAb fragment, a scFv fragment, an isolated CDR region, a dsFv diabody, a single chain antibody, and combinations thereof.

6. A kit comprising:

at least one antibody agent or antigen-binding fragment thereof according to claim 1; a syringe, needle, or applicator for administration of the at least one antibody or fragment to a subject; and instructions for use.

7. A method of manufacturing a pharmaceutical composition, the method comprising steps of:

providing an antibody agent or antigen-binding fragment thereof according to claim 1; and

formulating the antibody agent with at least one pharmaceutically acceptable carrier or excipient,

so that a pharmaceutical composition is generated.

8. An antibody agent or antigen-binding fragment thereof specific to Dengue virus, wherein the antibody agent comprises a heavy chain that is or comprises an amino acid sequence as set forth in SEQ ID NO: 21 and whose light chain is or comprises an amino acid sequence as set forth in SEQ ID NO: 22.

9. A composition comprising an immunoglobulin heavy chain of SEQ ID NO: 21 and an immunoglobulin light chain of SEQ ID NO: 22.

10. The antibody agent or the antigen-binding fragment thereof according to any one of claims 1-5 or 8, or the composition according to claim 9, for use in the treatment and/or prevention of Dengue virus infection.

11. Use of the antibody agent or the antigen-binding fragment thereof according to any one of claims 1-5 or 8, or the composition according to claim 9, in the manufacture of a medicament for the treatment and/or prevention of Dengue virus infection.